Similar to previous studies, which demonstrated that high expression levels of TGFβ1 were associated with poor prognosis in several cancers as well as GC (27, 28), further immunomodulatory gene analysis also indicated that TGFβ1 are significantly correlated with ASIRGPI and poor survival. This evidence concerns the gene TGFB1 and cancer.